Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 16/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 16/20 | 0.42 |
| ▸ | DRD2 | P14416 | 4/20 | 0.42 |
| ▸ | HRH1 | P35367 | 7/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17712726 | 0.81 | DRD3 (0.48) | DRD3KCNH2DRD2HRH1MEN1 | |
| SCHEMBL378206 | 0.80 | KCNH2 (0.61) | DRD3KCNH2DRD2HRH1 | |
| SCHEMBL14077075 | 0.77 | HSD11B1 (0.36) | RAB9AKMT2A | |
| SCHEMBL2307186 | 0.76 | KCNH2 (0.60) | DRD3KCNH2DRD2HRH1 | |
| SCHEMBL12377972 | 0.74 | HSD11B1 (0.35) | RAB9AKMT2A | |
| SCHEMBL378553 | 0.74 | DRD3 (0.54) | DRD3KCNH2DRD2MEN1NPC1 | |
| SCHEMBL2288693 | 0.73 | DRD3 (0.76) | DRD3KCNH2DRD2HRH1 | |
| SCHEMBL378338 | 0.73 | KCNH2 (0.77) | DRD3KCNH2DRD2CYP1A2 | |
| Hydrochloric Acid SCHEMBL2286365 | 0.73 | DRD3 (0.75) | DRD3KCNH2DRD2HRH1 | |
| SCHEMBL378370 | 0.73 | KCNH2 (0.77) | DRD3KCNH2DRD2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003638-B2 | 7-pyrazolylbenzazepines having affinity for D3 receptor | GLAXO GROUP LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| US-8003638-B2 | 7-pyrazolylbenzazepines having affinity for D3 receptor | GLAXO GROUP LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| US-8003638-B2 | 7-pyrazolylbenzazepines having affinity for D3 receptor | GLAXO GROUP LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| US-20080312213-A1 | 7-Pyrazolylbenzazepines Having Affinity For D3 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20080312213-A1 | 7-Pyrazolylbenzazepines Having Affinity For D3 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20080312213-A1 | 7-Pyrazolylbenzazepines Having Affinity For D3 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| EP-1758890-A1 | 7-PYRAZOLYLBENZAZEPINES HAVING AFFINITY FOR D3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123717-A1 | 7-PYRAZOLYLBENZAZEPINES HAVING AFFINITY FOR D3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312213-A1 | 7-Pyrazolylbenzazepines Having Affinity For D3 Receptor | DRD3, HTR3C, GRIN3A | DRD3 1/4885KCNH2 162/4885DRD2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.